Zacks: Concord Medical Services Hldg Ltd (NYSE:CCM) Given $2.00 Consensus Price Target by Analysts

Shares of Concord Medical Services Hldg Ltd (NYSE:CCM) have been given a consensus broker rating score of 3.70 (Sell) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell recommendation.

Brokers have set a 12-month consensus price target of $2.00 for the company and are expecting that the company will post ($0.03) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Concord Medical Services an industry rank of 12 out of 256 based on the ratings given to its competitors.

Separately, Zacks Investment Research cut Concord Medical Services from a “hold” rating to a “sell” rating in a research note on Monday, September 2nd.

CCM remained flat at $$2.49 during trading hours on Friday. The company had a trading volume of 49 shares, compared to its average volume of 3,956. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.63 and a current ratio of 1.64. The firm has a market capitalization of $104.51 million, a PE ratio of -2.08 and a beta of -0.19. Concord Medical Services has a 52-week low of $1.85 and a 52-week high of $3.84. The stock has a 50 day simple moving average of $2.53 and a 200-day simple moving average of $2.60.

A hedge fund recently raised its stake in Concord Medical Services stock. Renaissance Technologies LLC grew its holdings in shares of Concord Medical Services Hldg Ltd (NYSE:CCM) by 3.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 237,500 shares of the company’s stock after purchasing an additional 8,200 shares during the period. Renaissance Technologies LLC owned approximately 0.55% of Concord Medical Services worth $532,000 at the end of the most recent reporting period. 1.74% of the stock is owned by institutional investors.

About Concord Medical Services

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.

Featured Article: How do CD ladders protect against rising interest rates?

Get a free copy of the Zacks research report on Concord Medical Services (CCM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with's FREE daily email newsletter.